- Home
- PGNY vs IMCR Comparison
PGNY vs IMCR Comparison
Compare PGNY & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGNY | IMCR |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PGNY | IMCR |
|---|---|---|
| Price | $24.76 | $35.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $27.90 | ★ $64.30 |
| AVG Volume (30 Days) | ★ 1.4M | 430.3K |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.96 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,268,689,000.00 | $379,590,000.00 |
| Revenue This Year | $11.63 | $32.42 |
| Revenue Next Year | $9.52 | $11.17 |
| P/E Ratio | $40.86 | ★ N/A |
| Revenue Growth | 11.41 | ★ 28.11 |
| 52 Week Low | $17.98 | $23.15 |
| 52 Week High | $28.75 | $40.72 |
Technical Indicators
Market Signals| Indicator | PGNY | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 55.01 |
| Support Level | $24.62 | $32.00 |
| Resistance Level | $25.78 | $35.95 |
| Average True Range (ATR) | 1.18 | 1.51 |
| MACD | -0.22 | 0.35 |
| Stochastic Oscillator | 16.75 | 82.99 |
Price Performance
Historical ComparisonAbout PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.